A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
2022-06-27
عنوان الدراسة
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
داعم الدراسة
AstraZeneca
دواء الدراسة
Budesonide + Formoterol VS. Budesonide + Terbutaline
رقم بروتوكول الدراسة
D589SC00003
حالة الدراسة
Completed
موقع الدراسة
AFH-DH
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。